Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer
- 29 September 2018
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 63 (1) , 94-100
Abstract
The Thyroid Cancer Genome Atlas (TCGA) was a major project that significantly clarified the key underlying genetic aberrations in papillary thyroid cancer. It confirmed the previously known somatic mutations and gene fusions and disclosed additional genetic alterations that were previously unknown. Among the most significant novel genetic mutations were those in EIF1AX, PPM1D, and CHEK2.Keywords
This publication has 30 references indexed in Scilit:
- Genetic variants and mutations ofPPM1Dcontrol the response to DNA damageCell Cycle, 2013
- Highly prevalent TERT promoter mutations in aggressive thyroid cancersEndocrine-Related Cancer, 2013
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial TreatmentMedicine, 2012
- Chek2 DNA Damage Response Pathway and Inherited Breast Cancer RiskJournal of Clinical Oncology, 2011
- Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1Cancer Research, 2009
- High Rate of BRAF and RET/PTC Dual Mutations Associated with Recurrent Papillary Thyroid CarcinomaClinical Cancer Research, 2009
- The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid CancerPPAR Research, 2008
- Wip1 Phosphatase Modulates ATM-Dependent Signaling PathwaysMolecular Cell, 2006
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005